Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca

Ovarian Cancer Clinical Trial

Official title:

A Pilot Study of Intravenous and Intraperitoneal Chemotherapy Plus Abdominal Hyperthermia to Treat Optimally Debulked and Recurrent Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00787488
• Other study ID #: Pro00008510
• Status: Withdrawn
• Phase: N/A
• First received: November 6, 2008
• Last updated: November 10, 2014
• Start date: April 2009
• Est. completion date: April 2009

Study information

• Verified date: November 2014
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a pilot study aimed to test the feasibility and safety of administering combination chemotherapy with paclitaxel (both intravenously and intraperitoneally) and cisplatin (intraperitoneally) plus whole abdominal hyperthermia every 3 weeks in the treatment of optimally debulked, advanced or recurrent ovarian, primary peritoneal, and fallopian tube cancer patients.

Description:

Day 1 of each 21 day Cycle:

Paclitaxel 175 mg/m2 IV (infused over 3 hours)

Day 1 or 2 of each Cycle Adequate IV hydration with normal saline (1000 ml recommended)followed by intraperitoneal infusion of 500 ml normal saline through the IP port.

Cisplatin 75 mg/m2 reconstituted in 500 ml NS warmed to 37 degrees Celsius is infused IP (30 minute infusion)followed immediately by whole abdominal hyperthermia

Abdominal hyperthermia will be delivered using the BSD 2000 ellipse system to target temperatures of 40-42 degrees Celsius monitored via rectally and vaginally continuing for no greater than 60 minutes after maximal 30 minute warm-up phase. Total duration of hyperthermia will be no greater than 90 minutes.

Day 8:

Paclitaxel 60 mg/m2 IP. Paclitaxel will be diluted and filtered initially in 1000 ml of normal saline or D5W warmed to 37 degrees Celsius. For IP administration, the patient must receive an additional 1000 ml of normal saline degrees Celsius in the peritoneal cavity.

Cycles will be repeated every 3 weeks x 6 cycles. Patients will be followed until disease progression/recurrence or death.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 2009
• Est. primary completion date: April 2009
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 72 Years

Eligibility

Inclusion Criteria:

• Histologically diagnosed Stage III or Stage IV advanced, persistent, or recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

• Optimal debulking (< 1cm residual disease) of their disease within 6 weeks of the start of the study

• Patients must have received no more than 2 prior chemotherapy regimens with at least 4 weeks since prior chemotherapy

• GOG performance status 0, 1, or 2

• Patients must have normal organ and marrow function defined as:

• absolute neutrophil count >1,500/mcL

• platelets >100,000/mcL

• total bilirubin and creatinine <1.5 X institutional upper limit of normal(ULN)

• AST(SGOT)/ALT(SGPT)<3 X institutional ULN

Exclusion Criteria:

• Patients with biochemical recurrences or evidence of measurable disease

• Patients with suboptimal (>1 cm) residual disease

• Patients who have had chemotherapy within 4 weeks prior

• Receiving any investigational agents

• Known brain metastases

• Epithelial ovarian carcinoma of low malignant potential (borderline carcinomas)

• Uncontrolled intercurrent illness

• Prior radiation therapy

• History of other invasive or pre-invasive malignancies (except non-melanoma skin cancer) within the past 5 years

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Ovarian Cancer

Intervention

Device:
• Hyperthermia
Every 3 weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Mark Dewhirst

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Toxicity		6 months	Yes
Secondary	Clinically free of disease. Response definitions will be based on CA-125, clinical assessment, CT imaging		1 year	No